-
Posted: October 9th, 2024, 11:00pm UTC
Conditions: Iodine-resistant Thyroid Cancer; Meningioma; NETs
Interventions: Drug: 68Ga-TATE-RGD; Drug: 18-FDG
Sponsors: Peking Union Medical College Hospital
Recruiting
-
Posted: June 25th, 2024, 11:00pm UTC
Conditions: Neuroendocrine Tumors; Progression; Neuroendocrine Tumor Grade 1; Neuroendocrine Tumor Grade 2; Neuroendocrine Tumor of Pancreas; Neuroendocrine Tumor of the Lung; Neuroendocrine Tumor Carcinoid
Interventions: Drug: Everolimus 5 MG
Sponsors: AC Camargo Cancer Center
Recruiting
-
Posted: April 3rd, 2024, 11:00pm UTC
Conditions: Neuroendocrine Tumors
Interventions: Drug: Cessation of somatostatin analogues; Drug: Continuation of somatostatin analogues
Sponsors: Australasian Gastro-Intestinal Trials Group; Canadian Cancer Trials Group
Not yet recruiting
-
Posted: March 20th, 2024, 11:00pm UTC
Conditions: Neuroendocrine Tumors
Interventions: Other: Evaluation of blood levels of biomarkers of cardiac damage
Sponsors: European Institute of Oncology
Recruiting
-
Posted: February 22nd, 2024, 1:00am UTC
Conditions: Autoimmune Gastritis
Interventions: Other: oral administration of a compound digestive enzyme capsule; Other: oral administration of apple cider vinegar; Other: oral administration of both the compound digestive enzyme capsule and apple cider vinegar
Sponsors: Jianning Yao
Not yet recruiting
-
Posted: December 7th, 2023, 1:00am UTC
Conditions: Pancreas Adenocarcinoma; Small-cell Lung Cancer; Glioblastoma, IDH-wildtype
Interventions: Genetic: Long term survival multimodal analysis
Sponsors: Cure 51; Gustave Roussy, Cancer Campus, Grand Paris; Centre Leon Berard; Vall d'Hebron Institute of Oncology; Istituto Europeo di Oncologia; Charite University, Berlin, Germany
Recruiting